We’re delighted to add a summary of a recent event titled: Novel treatments for relapsed or refractory multiple myeloma in lenalidomide- and daratumumab- exposed patients.
The presentations were provided by a panel of international experts and local commentary is by Clinical Associate Professor Philip Campbell, Head of Clinical Haematology and Director of Cancer Services at University Hospital Geelong.
Please login below to download this issue (PDF)